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ABSTRACT
Diverse evidence from epidemiologic surveys and investigations into
themolecular basis of allergenicity have revealed that a small cadre of
“initiator” allergens promote the development of allergic diseases,
such as asthma, allergic rhinitis, and atopic dermatitis. Pre-eminent
among these initiatorsare thegroup1allergens fromhousedustmites
(HDM). In mites, group 1 allergens function as cysteine peptidase
digestive enzymes to which humans are exposed by inhalation of
HDM fecal pellets. Their protease nature confers the ability to activate
high gain signaling mechanisms which promote innate immune
responses, leading to the persistence of allergic sensitization. An
important feature of this process is that the initiator drives responses
both to itself and to unrelated allergens lacking these properties
through a process of collateral priming. The clinical significance of
group 1 HDM allergens in disease, their serodominance as allergens,
and their IgE-independent bioactivities in innate immunitymake these
allergens interesting therapeutic targets in the design of new small-
molecule interventions in allergic disease. The attraction of this new
approach is that it offers apowerful, root-cause-level intervention from
which beneficial effects can be anticipated by interference in a wide
range of effector pathways associated with these complex diseases.
This review addresses the general background to HDM allergens
and the validation of group 1 as putative targets. We then discuss
structure-based drug design of the first-in-class representatives of
allergen delivery inhibitors aimed at neutralizing the proteolytic effects
ofHDMgroup1allergens,whichareessential to thedevelopmentand
maintenance of allergic diseases.
Introduction
Over the past 40 years, pharmacology, immunology, and cell
biology have contributed enormously to understanding the
mechanisms of diseases with allergic etiologies, viz. atopic
dermatitis, allergic rhinitis, and much of asthma. The pharma-
cologic contribution to this research effort has created awealth of
newmolecular and biologic entities that have enjoyed success as
experimental tools. However, for new entities acting upon
unprecedented targets, this drugdiscovery enterprisehas largely
failed when assessed against themetric of clinical success. These
endeavors have revealed the inherent weakness in treating the
effects rather than causes of disease and have demonstrated
convincingly the difficulties faced whenmaking focused interven-
tions against strategic effectormechanisms that are backed up by
multiple redundancies. Indeed, the supremacy of inhaled cortico-
steroids as a standard of care for asthmahighlights the benefits of
a broad spectrum of action, but despite this, discrete targets in
downstream effector pathways continue to attract attention. The
more recent focus on interventions based on new biologic entities,
suchasmonoclonal antibodiesdirectedagainst interleukin5 (IL-5),
the shared IL-4/IL-13 receptor a-subunit, or thymic stromal
lymphopoietin (TSLP), has demonstrated that success with new
approaches is certainly feasible when patients are rigorously
stratified for treatment.Nevertheless, theoverarchingphilosophy
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ABBREVIATIONS: ADAM, A disintegrin and metalloprotease; ADI, allergen delivery inhibitor; ADZ 50,000, (S)-3-((S)-2-((S)-2-benzamido-3-
methylbutanamido)propanamido)-2-oxoheptyl-2,6-bis(trifluoromethyl)benzoate; Blo t, Blomia tropicalis; CCL, C-C chemokine ligand; CD, cluster of
differentiation; DC, dendritic cell; DC-SIGN, dendritic cell–specific intercellular adhesion molecule 3–grabbing nonintegrin; Der f, Dermatopagoides
farinae; Der p, Dermatophagoides pteronyssinus; DPI, dry powder inhaler; EMT, epithelial-mesenchymal transition; HDM, house dust mite; IL,
interleukin; LPS, lipopolysaccharide; MD-2, myeloid differentiation protein-2; MRGPR, Mas-related G-protein coupled receptor; n, native form; Nrf2,
nuclear factor (erythroid-derived 2)-like 2; PAR, protease-activated receptor; r, recombinant protein engineering; ROS, reactive oxygen species;
siRNA, small interfering RNA; TAK-242, ethyl-(6R)-6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate; Th2, type 2 T-helper cell;
TJ, tight junction; TLR, Toll-like receptor; TSLP, thymic stromal lymphopoietin.
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in thesenewly approved or emerging biologic approaches remains
directed at downstream effectors, and inevitably, the reminders
of the high risk of failure associated with this level of interven-
tion are ever present because not all anticytokine development
programs have enjoyed positive outcomes in asthma. This raises
strategic questions for the design of new approaches to these
diseases, and among the most challenging topics are the
identification of tractablenew targets and the future that remains
for small-molecule design in an era when biologics are in the
limelight.
Encouragingly, alternative philosophies have delivered suc-
cess, as demonstrated by omalizumab, the monoclonal antibody
therapy which depletes circulating IgE to eventually reduce the
amount of antibody bound to high-affinity IgE receptors onmast
cells. The development of omalizumab represented a significant
change from a focus on symptom amelioration to an upstream
intervention potentially capable of disease modification. How-
ever, among other significant issues, biologic therapies such as
omalizumab pose significant reimbursement challenges which
are problematic for patient access to treatment in chronic
diseases affecting large populations.
From a theoretical perspective, an ideal intervention would
target a root cause of allergic disease, namely, allergens them-
selves. This is, of course, partly the basis of the long-standing
practice of allergen-specific immunotherapy. For small-molecule
interventions, this root-cause approach has been generally viewed
as an unattainable goal: there are many allergens in the
environment, many of which remain poorly characterized, and
exactly why they are allergenic—that is, break immune tolerance
and promote IgE-directed immune responses—has, until relative-
ly recently, been a surprisingly unfashionable topic in allergy.
However, progress in the characterization of allergens has shed
new light on the molecular basis of allergenicity, and this has
coincided with a renaissance of interest in innate immunity. This
creates the possibility of making interventions at critical check-
points in these pathways to prevent the development of allergic
disease. In particular, it is now possible to design an approach to
target a major asthma trigger at root-cause level, with the
advantage that this circumvents concerns about the chronic
consequences of blocking checkpoints which are of fundamental
importance to immunity. Unlike allergen-specific immunother-
apy, an important advantage of this new line of attack is the
prevention of innate immune responses which are the engine of
allergy development. The purpose of this review is to examine the
biologic mechanisms by which a major house dust mite (HDM)
allergen triggers allergic disease, and describe the design of an
intervention to specifically neutralize this activity. The choice and
nature of the target are unprecedented and may be unfamiliar to
those outside the immediate field; therefore, as an aid to
interested newcomers, we also describe the historical background
to HDM allergens and allergic disease, their clinical significance,
and a brief overview of the complete spectrum of denominated
HDM allergens.
HDM Allergens and Disease
House dust is a complex mixture of biologically diverse
components from various sources with properties that render it
inhalablebyhumans.Housedust as a cause of allergic diseasewas
first recognized in 1921 by the American physician Richard Kern,
who observed that many patients with rhinitis or asthma had
positive skin reactions to extracts of dust from their own homes.
This idea was elaborated further in the following two decades by
Willem Storm van Leeuwen, Professor of Pharmacology and
Director of the Pharmacotherapeutic Institute at the University
of Leiden, who proposed that the cause of asthma could be the
presence of mites in house dust. However, conclusive proof
remained elusive until 1967, when Spieksma and Voorhorst and
their colleagues (Voorhorst et al., 1967) established that Derma-
tophagoides pteronyssinus was an important source of indoor
allergens—a linkage which we now regard as intuitive, but
which at the time was received with fierce skepticism from
many allergists. It is now recognized that HDMs such as
D. pteronyssinus or Dermatophagoides farinae form the single
most important indoor allergen source associated with asthma in
temperate climates and lead to the development of high-titer
allergen-specific IgE. The growth in sensitization of human
populations is, in part, promoted by indoor, sedentary, affluent
lifestyles and the creation of warm, humid, draft-free habitation
and working conditions which provide optimal growth conditions
forHDMs. Consequently,many people are extensively exposed to
HDMs with the result that allergic diseases triggered by indoor
allergens are major healthcare problems with a significant
socioeconomic impact.
Substantial evidence associates allergic conditions such as
asthma, chronic rhinitis, atopic dermatitis, and, less frequently,
conjunctivitis with exposure to HDM or other indoor allergens
(Smith et al., 1969; Platts-Mills et al., 1987, 1997; Sporik et al.,
1990; Gelber et al., 1993; Peat et al., 1996; Squillace et al., 1997;
Pichavant et al., 2005; Platts-Mills, 2009). Data from longitudinal
investigations suggest that the development of sensitization to
HDMoccurs before polysensitization (Silvestri et al., 1999; Purello-
D’Ambrosio et al., 2001), that is, thedevelopment of allergy to other
triggers, a phenomenon which occurs in ∼50%–80% of people
(Calderón et al., 2012). At first, this ordering of events in
polysensitization seems puzzling until it is recognized that the
bioactivity of certain allergens makes them unusually potent
stimulants and providers of collateral immune priming on which
other allergens depend. In this regard, certain HDM proteins
function broadly as bioinitiators as well as simply being allergenic.
HDMs are small arthropods, ∼250 mm in length, related to
spiders and scorpions.Manymite species are found in house dust,
but the pyroglyphid family dominates in most areas of the world
(e.g., D. pteronyssinus, D. farinae, and Euroglyphus maynei). In
the tropics, allergy to Blomia tropicalis may also be prevalent.
Dustmites live on a diet of exfoliated human skin flakes and other
biodebris. Existing on this diet means that HDMs have digestive
enzymes which can process tough structural proteins. Food waste
is excreted, together with the digestive enzymes, in pellets which
are of a respirable aerodynamic diameter (10–30 mm). As de-
scribed later, these excreted digestive enzymes are significant
because they are allergenic with a bioactivity profile which
provides them with the ability to promote sensitization to them-
selves and unrelated inhalant allergens, regardless of source.
Sensitization toHDMallergens occurs through inhalation of their
fecal pellets,which impact on theairway epitheliumwhereairway
surface liquid triggers the release of the pellet contents, resulting
in a high concentration of allergen at the site of deposition.
Sensitization by inhalation may also be the case in people who
develop atopic dermatitis rather than allergic conditions of the
airways, although in established dermatitis, any ensuing allergic
responses are more likely to result from skin contact.
Allergen Nomenclature. Allergens are classified accord-
ing to a system devised in 1984 by the Allergen Nomenclature
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Sub-Committee, which was established jointly by the World
HealthOrganization and the InternationalUnion of Immunologic
Societies. The systematic naming of allergens takes the accepted
binomial nomenclature of the source and uses the first three
letters of the genus combinedwith the first one or two letters of the
species name followed by an Arabic numeral reflecting the order
in which the allergenwas isolated or its clinical importance (or, in
reality, a hybrid of both). This numbering allows the denomina-
tion of allergens by group. In the case of Dermatophagoides
pteronyssinus, the systematic naming takes the form Der p X,
where X is the group number, and this is replicated in similar
allergens from related species. Thus, HDM cysteine protease
allergens fromD. pteronyssinus,D. farinae, Euroglyphus maynei,
and Blomia tropicalis are known individually as Der p 1, Der f 1,
Eurm1, andBlo t 1, respectively; collectively as the group 1HDM
allergens; or as the HDM cysteine proteases. Denomination is
further resolved to accommodate the allelic variation in proteins,
which gives rise to isoallergens. Those allergens from the same
source species with .67% sequence identity are denoted using
suffixes which may be up to four digits in length according to the
complexity of the isoallergenic variations (e.g., Der p 1.0101, Der p
1.0102, etc.). As an additional refinement, it is sometimes
necessary to denote whether allergens are in their native (n)
forms or are products of recombinant protein engineering (r).
Recombinant allergens differ most notably in protein glycosyla-
tion, which is usually due to the need to modify potential
glycosylation sites, e.g., to prevent hyperglycosylation of proteins
expressed in yeast, an expression system which is often favored
because it generally provides correct protein folding and thus
mimics conformational epitopes and other biologic characteristics
seen in native allergens. Whereas some glycosylation changes
may have neutral or little impact on bioactivities such as the
protease behavior of Der p 1 (Zhang et al., 2009), they are more
relevant to the processing of allergens by antigen-presenting cells.
Thus, the prefixes n and r, respectively, may be appended (e.g.,
nDer p 1, rDer p 1).
More than 30 groups of HDM allergens have now been
denominated, making HDMs probably the single largest
source of allergens to which humans are exposed. These
allergens do not, however, have equal clinical importance
because a clear serodominance is observable for those belong-
ing to groups 1 and 2. A summary of HDM allergens and their
properties is provided in Table 1. Molecular biology, genomics,
and bioinformatics have played key roles in the elucidation
of these groups, particularly in predicting their functional
properties in the host—information which provides important
insights into why those molecules behave as allergens in
humans. Further information about the characteristics of
these allergen groups can be obtained by using the GenBank
and UniProt accession codes listed in Table 1.
Group 1 HDM Allergens as a Drug Design Target
As clan CA, C1 family cysteine proteases, group 1 HDM
allergens have a basic structure, comprising a substrate-
binding groove separating two globular domains, which is
archetypally defined by the extensively studied representa-
tives, papain, actinidin, and cathepsin K. Proteolytic latency
of the HDM allergens is maintained in the proenzyme form
because the prodomain occludes the catalytic center of the
enzyme while covalently tethered to the rest of the molecule,
and in so doing, it masks some IgE epitopes. This results in
proteolytically latent HDM allergens being less immunogenic
than their catalytically competent mature forms (Takai et al.,
2005). Differences in prodomain structure between the HDM
allergens and cathepsins have functional implications which
place them in an identifiable subfamily of C1 enzymes
(Zhang et al., 2007). The group 1 allergen prodomains from
Dermatophagoides species comprise 80 amino acids arranged
as four a-helices. Thus, they can be distinguished from
cathepsins K, L, and S, in which the longer propieces comprise
only three a-helices and contain a conserved “ERFNIN”motif
[EX3RX2 (I/V)FX2NX3IX3N] that is absent in the HDM
allergens (Zhang et al., 2007). Other cathepsins, notably
cathepsin B, have prodomains which lack a further a-helix
and which are shorter than the HDM allergens. In cathepsins,
untethered propeptide units generally behave as regulators of
their cognate proteases, but this seems not the case in Der p
1 (and, by inference, other group 1 HDM allergens) where
maturation of the protease results in rapid degradation of
the propiece and unconstrained enzymatic activity (Zhang
et al., 2007). The corresponding group 1 allergen Blo t 1
of B. tropicalis, found only in tropical regions, represents an
intermediate casebetween themorepervasiveDermatophagoides
group 1 allergens and cathepsins. At the time of writing,
catalytic competence of Blo t 1 is only inferred from alignment
of its putative catalytic residues (C119 H263 N283) with Der p 1,
and formal proof of the enzymatic activity of unambiguously
pure allergen is awaited. It differs from its Dermatophagoides
counterparts in sharing only ∼30% sequence identity overall
and having a modified ERFNIN motif (ERFQVN), which may
indicate that its prodomain could remain a potential inhibitor
after maturation, restricting its behavior. In that regard, it is
noteworthy that although Blo t 1 is clearly a major allergen of
B. tropicalis, it is not obviously serodominant, unlike the
group 1 HDM allergens. It is tempting to speculate that the
lack of serodominancemay be related to inferences that can be
drawn about control of its proteolytic capacity.
Of numerous difficulties encountered in studying the biology of
allergens, a fundamental challenge is their purification from the
complex mixture of bioactive materials with which they are
normally associated. Although such extraneous materials may
have deep relevance to host immune responses and disease
development, they can be serious confounding factors when
investigating functions and mechanisms at the molecular level.
A pertinent example was the claim, which has enjoyed a
persistence in some literature, that Der p 1 is a multifunctional
proteasewith both cysteine and serine protease activities (Hewitt
et al., 1997). It is now clear that this is incorrect: no evidence for
this notion exists within the crystal structure of Der p 1, and
studies with native and recombinant Der p 1 in the presence of
highly selective inhibitors provide no functional support. The
likeliest explanation for the misleading claim is that the native
Der p 1 preparation studied by those researchers was contami-
nated with serine peptidase allergens because native Der p
1 prepared by a strategy to rigorously eliminate such contami-
nation fails to degrade the chymotrypsin substrate N-succi-
nyl-AAPF-p-nitroanilide. In contrast, both trypsin andDer p 1
degradeN-Bz-FVR-p-nitroanilide, butwhereasDerp1 is inhibited
by (S)-3-((S)-2-((S)-2-benzamido-3-methylbutanamido)propa-
namido)-2-oxoheptyl-2,6-bis(trifluoromethyl)benzoate (ADZ
50,000), it is not affected by a generic serine peptidase inhibitor,
aminoethylbenzenesulfonyl fluoride, which blocks the action of
trypsin (our unpublished data).
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TABLE 1
Group denominations of HDM allergens, with exemplars, and their bioactivity profiles based on bioinformatics predictions and/or empirical
observations
The list omits storage mite species exemplars of the subclass Acari, although in many cases their allergens show the same grouping and characteristics as the HDM allergens.
Exemplar GenBank and UniProt accession codes of the listed allergens are provided for supporting literature references and bioinformatics substantiation (e.g., by hyperlink
to simple modular architecture research tool “SMART”), but codes for isoallergenic variants are omitted for brevity.
HDM Allergen Group Exemplars Molecular Mass Known or Predicted Bioactivity GenBank/EMBL UniProt
kDa
Group 1, e.g., Der p 1 25 (39 Blo t 1) Cysteine protease U11695 P08176
Der f 1 AB03496 Q58A71
Eur m 1 AF047610 P25780
Der m 1 — P16312
Blo t 1 AF277840 Q95PJ4
Group 2, e.g., Der p 2 14 NPC2 family; MD-2–related protein,
lipid binding, binds LPS
AF276239 P49278
Der f 2 D10447 Q00855
Eur m 2 AF047613 Q9TZZ2
Blo t 2 AY288141 Q1M2P1
Group 3, e.g., Der p 3 25 Trypsin U11719 P39675
Der f3 D63858 P49275
Eur m3 AF047615 O97370
Blo t 3 AY291323 A1KXI1
Group 4, e.g., Der p 4 60 Amylase AF144060 Q9Y197
Der f 4 KM016832 A0A089FLV3
Eur m 4 AF144061 Q9Y196
Blo t 4 AY291324 A1KXI2
Group 5, e.g., Der p 5 14 Function unknown; ligand-binding protein? S76337 P14004
Blo t 5 U59102 O96870
Group 6, e.g., Der p 6 25 Chymotrypsin — P49277
Der f 6 AF125187 P49276
Blo t 6 AY291325 A1KXI3
Group 7, e.g., Der p 7 26–31 Bactericidal permeability-increasing
like protein of unknown function; belongs
to the juvenile hormone binding family of
proteins found in insects; may have
lipid-binding properties
U37044 P49273
Der f 7 S80655 Q26456
Blo t 7 MF740745 —
Group 8, e.g., Der p 8 27 Glutathione S-transferase S75286 P46419
Der f 8 KC305499 L7V2G7
Blo t 8 GQ398117 C8CGT7
Group 9, e.g., Der p 9 29 Collagenase-like serine protease AY211952 Q7Z163
Group 10, e.g., Der p 10 36 Tropomyosin Y14906 O18416
Der f 10 D17682 Q23939
Blo t 10 EU106615 A7XZI4
Group 11, e.g., Der p 11 103 Paramyosin AY189697 Q6Y2F9
Der f 11 AF352244 Q967Z0
Blo t 11 AF525465 Q8MUF6
Group 12, e.g., Blo t 12 14 Possible chitinase; shows homology with
Der f 15 due to chitin-binding domain
U27479 Q17282
Group 13, e.g., Der p 13 15 Fatty acid–binding protein HM560018 E0A8N8
Der f 13 AY283293 Q1M2P5
Blo t 13 U58106 Q17284
Group 14, e.g., Der p 14 177 Vitellogenin or lipophorin AF373221 Q8N0N0
Der f 14 D17686 Q94507
Eur m14 AF149827 Q9U785
Group 15, e.g., Der p 15 98, 109a GH18 superfamily chitinase; shows homology
with mite group 18.
DQ078741 Q4JK69
Der f 15 AF178772 Q9U6R7
Group 16, e.g., Der f 16 53 Gelsolin/villin AF465625 Q8MVU3
Group 17, e.g., Der f 17 30 Calcium-binding protein — —
Group 18, e.g., Der p 18 60 GH18 superfamily chitinase; homologous
with group 15
DQ078739 Q4JK71
Der f 18 AY093656 Q86R84
Group 19, e.g., Blo t 19 7 Antimicrobial peptide homology KF771884 W5RZ24
Group 20, e.g., Der p 20 40 Arginine kinase EU684970 B2ZSY4
Der f 20 KM009994.1 —
Group 21, e.g., Der p 21 14 Function unknown; shows homology with
group 5 allergens
DQ354124 Q2L7C5
Der f 21 KF732965.1 B2GM84
Blo t 21 DQ788679 A7IZF1
Group 22, e.g., Der f 22 17 Shows homology with group 2 mite allergen;
belongs to MD-2–related lipid recognition
domain family; implicated in lipid binding
DQ643992 A5X5X4
Group 23, e.g., Der p 23 14–19 Unknown function; shows homology with
peritrophin-A domain and contains a
chitin-binding domain
EU414751.1 L7N6F8
Der f 23 KU166910 —
Group 24, e.g., Der p 24 13 Ubiquinol-cytochrome c reductase binding
protein-like protein
KP893174 A0A0K2GUJ4
Der f 24 KC669700 M9RZ95
Group 25, e.g., Der f 25 34 Triosephosphate isomerase KC305500.1 L7UZA7
Group 26, e.g., Der f 26 18 Myosin alkali light chain KM009996b A0A088SAG5b
Group 27, e.g., Der f 27 48 Serpin–trypsin inhibitor AIO08851 —
(continued )
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The cleavage specificity of Der p 1 has been evaluated in
peptide sequences from suspected target proteins and by library
screening campaigns. Substrates in a combinatorial library of
general formula Abz-1-2-3-4-Y(NO2)-D-NH2, with cleavage be-
tween residues 3 and 4, revealed the following preferences forDer
p 1: 1) V.A,Q,L,F; 2) A..Q or K; 3) L, J, or A.S; and 4) S.
Noting that J is an isostere of K, these findings are similar to the
results of screening crude HDM extracts in a different combina-
torial library where the preferences for the S1-S4 pockets were K,
A, V, and J, respectively. A more recent campaign using phage
display has proposed a preference for K/R,V,L/V,V,V for the S1-S5
pockets and used a bioinformatics approach to predict potential
cellular substrates, some of which have not previously been
revealed by hypothesis-driven investigation (Jacquet et al., 2017).
Although informative about the selectivity or promiscuity of
enzyme pockets, this information does not, of course, translate
directly into obvious function or provide immediate chemical
design solutions for inhibitor discovery. Potential substrates may
be clandestine in cellular reality and, therefore, of marginal
biologic significance. Conversely, apparently disfavored sub-
strates may be presented in ways which encourage attack or
whose cleavage initiates amplification mechanisms which trans-
form the wider biologic significance of the target. For inhibitor
design, anappreciation of thebinding site topology taken together
with substrate preferences is merely a first step in the creation of
developable chemical entities as opposed to tool compounds
whose value is restricted.
Examination of the structure of Der p 1 determined from
crystals of isoallergen Der p 1.0105 reveals the presence of three
disulphide bridges (C84-C197, C111-C151, and C145-C183) and sug-
gests that the amino acid residues surrounding the substrate-
binding groove, with its characteristic catalytic triad of C114, H250,
and N270, are well conserved. The clear implication is that
substrate preferences are consistent among isoallergens in a
single species of HDM and between homologous allergens in
different HDM species. This is supported by enzyme kinetic and
inhibitor data (our unpublished data) and structural comparison
of the active sites of Der p 1 andDer f 1, where substitution of R231
in Der p 1 by Q232 is the most notable difference.
High-resolution structural data allow the binding pockets of
Der p 1 to be compared with off-target enzymes which have the
potential to constitute selectivity nuisances in drug design. An
empirical observation made in early discovery research was that
nonoptimized inhibitors of Der p 1 were effective inhibitors of
cathepsin B but showed good selectivity over cathepsins S and K.
We believe that the selectivity of our initial inhibitors over
cathepsins S and K was imparted to some extent by a small P2
group, whereas cathepsins S and K prefer larger groups in this
position. Despite cathepsin B being the least like Der p 1 when
judged by amino acid sequence, optimization of selectivity over
cathepsin B requires more chemical design effort to exploit the
greater openness of the S3 pocket in Der p 1 which results from
substitution by T74 in place of the bulkier Y75 in cathepsin B. The
appreciation of these differences provided encouragement that
novel inhibitors of theHDMallergenswith appropriate selectivity
profiles were achievable.
While not compromising the view that they are a single target
for structure-based protease inhibitor design, detailed crystallo-
graphic investigations have revealed some minor differences
between Der p 1 and Der f 1. Examples include the presence of a
binding site for divalent cations which may be occupied in the
case of Der p 1, but notDer f 1 (Meno et al., 2005, 2006; deHalleux
et al., 2006; Chruszcz et al., 2009). Removal of divalent cations
doesnot alter theproteolytic activity ofDerp1 (unpublisheddata),
which distinguishes it from papain in which divalent cations
increase catalytic activity (Chruszcz et al., 2009). A further
distinction between Der p 1 and other cysteine peptidases is its
tendency to form oligomers in solution or in crystalline solid state
(de Halleux et al., 2006; Chruszcz et al., 2009), although Der f 1
lacks this behavior (Chruszcz et al., 2009). Whether this oligomer-
ization has biologic significance is unknown—the property is
uncommon in cysteine peptidases generally, with cathepsin C
being one of the few enzymes where it may be physiologically
relevant. Although the IgE-binding epitopes of these allergens
remain to be fully defined, structural analysis of a monoclonal
antibody which binds both Der p 1 or Der f 1 shows that
mutagenesis of the conserved allergen-binding site diminishes
IgEbinding, providing insight intoasurface regionwhichprovides
linear and/or conformational features for species cross-reactivity
between Der p 1, Der f 1, and E. maynei 1 (Chruszcz et al., 2012).
This region is distant from the catalytic sites of these allergens,
suggesting that IgE-bound allergens are catalytically active,
TABLE 1—Continued
HDM Allergen Group Exemplars Molecular Mass Known or Predicted Bioactivity GenBank/EMBL UniProt
Group 28, e.g., Der f 28 70 Heat shock protein KC305502 L7V065
Group 29, e.g., Der f 29 16 Peptidyl-prolyl cis-trans
isomerase (cyclophilin)
AY283280.1 A1KXG2
Group 30, e.g., Der f 30 16 Ferritin KC305503 L7UZ91
Group 31, e.g., Der f 31 15 Cofilin, actin binding protein KM010014 A0A088SAY1
Group 32, e.g., Der f 32 35 Secreted inorganic pyrophosphatase KM009993 A0A088SCP3
Group 33, e.g., Der f 33 52 a-tubulin KM010005 A0A088SV41
Group 34, e.g., Der f 34 16 Enamine/imine deaminase LC120618 A0A1J1DL12
Group 35, e.g., Der f 35 14 MD-2–related protein homologous
with group 2
LC175222 A0A1W7HBY9
Group 36, e.g., Der p 36 42 Function unknown; contains a
C-terminal C2 domain
(pfam00168) associated with
signal transduction
KY465507 A0A291KZD3
Der f 36 KY465506 A0A291KZC2
Group 37, e.g., Der p 37 30 Peritrophic-like protein domain MG520330c —
EBML, European Molecular Biology Laboratory.
aGlycosylated forms of 63-kDa protein predicted by DNA sequence.
bNote that GenBank/European Bioinformatics Institute and UniProt incorrectly designate this as a group 30 allergen. Definitively, it is a group 26 allergen as designated by
the Allergen Nomenclature Sub-Committee of the World Health Organization and International Union of Immunologic Societies. Please refer to http://www.allergen.org/
viewallergen.php?aid=815 for further information.
cAccession not yet published.
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TABLE 2
Allergy-related biologic actions and effects evoked by HDM protease allergens
Sphere of Action Action or Effect Allergen or Extract References
Mucosal defense Cleavage of tight junctions/reduced
epithelial barrier function/allergen
delivery
HDM fecal pellet extract,
Der p 1, Der f 1,
Der p 3, Der p 6
Herbert et al. (1990, 1995), Winton et al.
(1998), Wan et al. (1999, 2000, 2001),
Nakamura et al. (2006); ADI
program—data on file
Disruption of epithelial
adherens junctions
Der p 1 (directly and
indirectly via ADAM 10)
Wan et al. (1999); ADI
program—data on file
Inactivation of airway
antiproteases
Der p 1 Kalsheker et al. (1996), Brown et al. (2003)
Epithelial-mesenchymal
transition
HDM extract Heijink et al. (2010a), Frisella et al. (2011)
Inactivation of surfactant
proteins
Der p 1, Der f 1 Deb et al. (2007)
IgE-independent mast cell
stimulation
Der p 1, HDM extract Machado et al. (1996)
Activation of NLRP3
inflammasome and apoptosis
HDM extract, Der p 1 Winton et al. (1998), Baker et al. (2003),
Frisella et al. (2011)
Cell signaling Prothrombinase activity HDM fecal pellet
extract, Der p 1
Zhang et al. (2016, 2018)
PAR-1 and PAR-4 activation Der p 1 (indirectly as
prothrombinase)
Zhang et al. (2016); ADI
program—data on file
PAR-2 activation HDM fecal pellet extract,
Der p 1, Der p 3, Der p 9
Sun et al. (2001), Asokananthan et al.
(2002), Jeong et al. (2008), Kato et al.
(2009), Cho et al. (2012), de Boer et al.
(2014), Post et al. (2014), Zhang et al.
(2016), Reddy and Lerner (2017)
PAR-1 inactivation Der p 1 Asokananthan et al. (2002)
PAR-2 inactivation Der p 1 Adam et al. (2006), Kato et al. (2009)
PAR-1 and PAR-2 upregulated
expression
Der p 1 Shi et al. (2010)
Mas-related G-protein–coupled
receptor activation
Der p 1 Reddy and Lerner (2017)
EGFR activation in epithelial cells Der p 1 (indirectly as
prothrombinase)
Zhang et al. (2016, 2018); ADI
program—data on file
Pannexon gating in epithelial cells Der p 1 (indirectly as
prothrombinase)
Zhang et al. (2016, 2018); ADI
program—data on file
ATP release from epithelial cells Der p 1 (indirectly as
prothrombinase)
Zhang et al. (2016, 2018); ADI
program—data on file
ADAM 17 activation in epithelial cells Der p 1 (indirectly as
prothrombinase)
Chen et al. (2017), Zhang et al. (2018)
ADAM 10 activation in epithelial cells Der p 1 (indirectly as
prothrombinase)
Chen et al. (2017); ADI
program—data on file
ADAM 8 activation in epithelial cells Der p 1 (indirectly as
prothrombinase)
ADI program—data on file
Cleavage of low-affinity
IgE receptor (CD23)
Der p 1 (directly and
indirectly via ADAM 10)
Schulz et al. (1995); ADI
program—data on file
Activation of endogenous
interstitial prothrombinase
HDM extract (due to Der p 1) Zhang et al. (2016); ADI
program—data on file
Regulation of gene expression
and exploitation of
antioxidant deficits
ROS generation Intracellular ROS by HDM
fecal pellet extract, Der
p 1 in epithelial cells,
Der f 1 in neutrophils
Fukunaga et al. (2011), Zhang et al.
(2016, 2018), Chen et al. (2017)
Immune activation and
allergic polarization
Breaking of immune tolerance HDM extract, Der p 1 Gough et al. (1999, 2001, 2003); ADI
program—data on file
Suppression of indoleamine
2,3-dioxygenase
Der p 1 Maneechotesuwan et al. (2009)
TLR4 ligation HDM extract, Der p 1 (indirectly
as prothrombinase)
Zhang et al. (2018); ADI
program—data on file
Bioactivating cleavage of IL-33 Der p 1 Cayrol et al. (2018)
Cytokine/chemokine expression
and release (e.g., IL-33, TSLP,
CCL2, CCL20, GM-CSF, IL-8,
IL-13, etc.)
HDM extract, Der p 1,
Der p 3, Der p 6, Der p 9
King et al. (1998), Pichavant et al. (2005),
Adam et al. (2006), Kauffman
et al. (2006), Ogawa et al.
(2008), Kato et al. (2009), Shi et al.
(2010), Arlian and Morgan (2011);
ADI program—data on file
Cleavage of IL-2R (CD25) Der p 1 Schulz et al. (1998)
Antigen-presenting cell
recruitment and activation
Dendritic antigen-presenting cell
recruitment
HDM extract, Der p 1 Pichavant et al. (2005), Robinson et al.
(2012); ADI Program—data on file
Cleavage of DC-SIGN/DC-SIGNR Der p 1 Furmonaviciene et al. (2007)
Interaction with viral RNA
sensors
Transductional convergence with
signaling from TLR3 and TLR7
HDM fecal pellet extract,
Der p 1
Zhang et al. (2018); ADI
Program—data on file
(continued )
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creating the potential for the exercise of multiple bioactivities
when interacting with sentinels such as mast cells and basophils.
A further feature of this site is its poor conservation in Blo t 1,
consistent with the low cross-reactivity of Blomia and Dermato-
phagoides allergens in allergic sera (Chruszcz et al., 2012).
Allergy Initiators: Biologic Effects of Group
1 HDM Allergens
For any protein to merit interest as a drug design target, a
minimum requirement is that plausible evidencemust exist to
validate its association with a disease-related pathway. For group
1 HDM allergens, a clear association of the allergen with disease
throughprecedented (i.e., IgE-dependent)mechanisms is historical
reality, and persuasive contemporary evidence now links proteo-
lytic activity to mechanisms considered core to the pathogenesis of
allergy.Theseare summarized inTable2andexamined indepth in
the subsequent sections. For these reasons, the group 1 HDM
allergens may be considered “initiator” allergens, a highly exclu-
sive cadre whose actions underpin and facilitate progressive
polysensitization to allergens from unrelated sources (although
the number of people exhibiting monosensitization is also signifi-
cant). It is clear from Tables 1 and 2 that the HDM allergen
repertoire contains three serine proteases which replicate some of
the effects of the group 1 cysteine proteases. In the airways, the
nature of this redundancy underscores the selection of group
1 HDM allergens as the favored target, because the latter enable
the redundancy of the serine peptidases through their ability to
inactivate airway serpins while evading antiprotease defenses
themselves. This provides a basis to anticipate that inhibition of a
group 1 allergen will boost the defense against serine peptidase
allergens by serpins. As discussed later, the correct proposal of
protease target is endorsed by encouraging data for group
1 inhibitors in a variety of mechanistic models.
Mucosal Defenses. Antigen-presenting cell networks of the
lung (dendritic cells) and skin (Langerhans cells) are the sentinels
which link innate and adaptive immune responses. These cells
process signals fromactivated innate immunemechanisms, suchas
pattern-recognition receptors, and present antigen to T cells after
theirmigration to lymphnodes.Tominimizenuisance triggeringby
low-grade external threats or the host microbiome, antigen-
presenting cells and pattern-recognition receptors exhibit a polar-
ized distribution, with many of these receptors and cells protected
by the epithelium. Epithelial cells, airway macrophages, and
components of airway surface liquid are thus the front line of
defense against allergens and other immunologic threats. In
understanding the initiation of sensitization and the processes
which ensure its persistence, a key question is how allergens
contact antigen-presenting cell networks, either by crossing muco-
sal barriers themselves or by promoting the ability of antigen-
presenting cells to sample from the external environment. Of all
allergens, the proteases ofHDMhave been themost studied in this
regard, notably in the airways whose simple epithelial structure,
intercellular junctions, and permeability characteristics are well
characterized.Themore complex stratifiedepitheliumof skin is less
extensively studied in the context of allergen disposition, reflecting
that the role of tight junctions (TJs) in regulating skin permeability
was itself unclear until the beginning of this millennium.
The first detailed studies of HDM allergen interactions with
epithelial cells used a combination of functional, biochemical,
and two-photon molecular excitation microscopy with three-
dimensional isosurface image reconstruction, although earlier
examination of permeability effects had been reported several
years earlier (Herbert et al., 1990, 1995; Wan et al., 1999, 2000,
2001). These investigations revealed that TJs in human airway
epithelial cells exposed to HDM fecal pellets were cleaved under
conditions that mimic daily exposure to the allergens (Fig. 1),
resulting in a nonspecific increase in paracellular permeability
(i.e., the barrier becomes leaky to all allergens, regardless of
origin, and may also facilitate dendritic, and other, cell migra-
tion). The underlying mechanism is a proteolytic attack by
cysteine peptidase and serine peptidase HDM allergens on the
extracellular domains of occludin and claudins (Wan et al., 1999,
2001), transmembrane proteins which form the contiguous
intercellular contacts at the apical pole of the cells and which
are adhesive components of the supramolecular TJ complex. In
turn, this extracellular proteolytic cleavage initiates intracellular
processing of the TJ plaque protein, ZO-1. Whereas epithelial
permeability control is likely to depend on the ensemble function
of various TJ adhesion proteins, lung-specific claudin-18 is
known to be important in the type 2 T-helper cell (Th2)–high
asthma phenotype. In common with claudins of TJs in other
tissues, claudin-18 is downregulated by IL-13 (whose release is
augmented by peptidase allergens), and its loss impairs epithe-
lial permeability control in model systems in vitro and in vivo
(Sweerus et al., 2017). Thus, the ability of protease allergens to
cleave TJs directly and to affect their function through cytokine
expression provides a powerful mechanism to compromise
epithelial defense. As described later, this is accompanied by
protease-driven inflammatory events in which the intracellular
generation of reactive signaling molecules plays a key role
and which provides a link to the activation of Toll-like receptor
4 (Fig. 1; Table 2).
An analogous mechanism operates in skin where HDM pro-
tease allergens cause the epidermis to become leaky and then
impede its restitution (Nakamura et al., 2006; Jeong et al., 2008),
TABLE 2—Continued
Sphere of Action Action or Effect Allergen or Extract References
Effector mechanisms Leukocyte recruitment Der p 1, HDM extract Robinson et al. (2012), Newton et al.
(2014); ADI program—data on file
Kinin generation from low- and
high-molecular-weight kininogens
Der f 3 Takahashi et al. (1990), Maruo et al.
(1991), Maruo et al. (1993)
Decreased cysteine protease
inhibitory activity of kininogens
Der f 3 Maruo et al. (1993)
Anaphylatoxin generation Der f 3 Maruo et al. (1997)
IgE-independent “pseudoallergic”
bronchoconstriction
Der p 1, HDM extract ADI program—data on file
DC-SIGNR, DC-SIGN receptor; EGFR, epidermal growth factor receptor; GM-CSF, granulocyte macrophage-colony stimulating factor.
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Fig. 1. (A and B) Three-dimensional isosurface reconstruction of fluorescent antibody labeling of TJs (green) and desmosomes (red) in human airway
epithelial cells. Normal cells are shown in (A); note the contiguous rings of TJs compared with the punctate staining of desmosomes. (B) Two hours after
exposure to HDM allergen, note the loss of TJ staining, whereas desmosomes remain intact. (C and D) Human airway epithelial cells labeled with
NucBlue and MitoSOX red (Life Technolgies, Renfrewshire, UK) in the absence of HDM allergen stimulation (C) or following exposure to mixed HDM
allergens showing generation of intracellular ROS (D). (E) Progress curves showing formation of rhodamine in calu-3 cells loaded with dihydrorhodamine
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while at the same time promoting cytokine and chemokine
production, which is similar to the response in airways (Arlian
et al., 2008; Ogawa et al., 2008; Oshio et al., 2009; Arlian and
Morgan, 2011) (Table 2). The cleavage of TJs in keratinocytes
affords the opportunity for Langerhans cells, which express TJ
proteins themselves, to form new TJs with keratinocytes,
enabling an upregulation of antigen sampling while, at least
initially, retaining barrier integrity (Kubo et al., 2009). Similar
behavior occurs in allergic rhinitis where, unlike nonrhinitic
controls, the dendrites of antigen-presenting cells penetrate
beyond the apical surface of the nasal epithelium (Takano et al.,
2005). However, chronic allergen exposure or other predisposing
factors for epithelial leakiness, such as loss of function mutations
in filaggrin or dysregulation of lipid composition in the stratum
corneum of the skin, result in augmented immunologic respon-
siveness to allergens. Indeed, emerging evidence suggests that
clinically unaffected skin barrier properties in atopic dermatitis
are compromised, as decreased levels of claudins-1, -4, and -23
have been found in nonlesional skin, and an inverse relationship
between claudin-1 and Th2-polarized responses has been ob-
served (De Benedetto et al., 2011; Brandner et al., 2015).
Although the allergen repertoire of HDMs consist of several
proteases, the particular importance of group 1 allergens, such
as Der p 1, is indicated by the prevention of transepithelial
delivery of allergen when TJ cleavage is blocked (Wan et al.,
1999), and when the proteolytic activity of Der p 1 is inhibited,
intranasally administered HDM allergens no longer evoke
allergic sensitization in mice. Thus, the serine protease HDM
allergens, despite cleaving TJs (Wan et al., 2001), have a
subordinate role in driving allergic sensitization.
In addition to the physical defenses, epithelial surfaces offer
protection against pathogens through biochemical mecha-
nisms (Table 2). Antiproteases are one facet of biochemical
defense relevant to interactions with protease allergens,
especially in the airways where epithelial surface liquid is
rich in a1-antitrypsin capable of inhibiting the effects of serine
protease allergens. However, Der p 1 inactivates this serpin
and is itself resistant to most mammalian antipeptidases
except a2-macroglobulin, whose molecular weight restricts its
presentation at the airway surface (Kalsheker et al., 1996;
Brown et al., 2003). Other targets of Der p 1 in airway surface
liquid are surfactant proteins –A and –D, members of the
collectin family of C-type lectin receptors. The function of
these proteins in innate immunity is opsonization of patho-
gens for phagocytosis, but as their names imply, they also
control surfactant production and may offer some protection
against allergy development (Deb et al., 2007).
Cell Signaling and HDM Protease Allergens. In addi-
tion to the events that promote the physical interaction of
allergens with antigen-presenting cells, HDM protease aller-
gens initiate a sophisticated series of events within the sphere
of innate immunity. Cells that are in the front line of
interactions with allergens (viz. macrophages, epithelial cells,
keratinocytes, dendritic cells, and mast cells) express an
extensive palette of innate immune receptors which are
central to the events that initiate and perpetuate allergy.
Cytokine production is one of their outputs with a prominent
role in progressively driving disease symptoms and exacerba-
tions. The main goal of clinical management in allergy is
prevention of exacerbations, so interruption of this chain of
events at key checkpoints should offer significant patient
benefit.
Group 1 HDM Allergens Are Prothrombinases. Un-
expectedly, one of the proteolytic features of Der p 1 is its
ability to behave as a prothrombinase, forming thrombin from
prothrombin independently from classic coagulation pathways
(Zhang et al., 2016) (Table 2). In airway epithelial cells, this effect
of Der p 1 is augmented by the subsequent activation of an
endogenous prothrombinase, which plays a major role in control-
ling the generation of reactive signaling molecules (Zhang et al.,
2018). These recent discoveries cast an exciting new perspective
on how group 1 HDM allergens upregulate cytokine expression
through the operation of a signaling cycle which interlinks
components having a pleiotropic role in allergy specifically, or
innate immunity generally (Fig. 2A). At the time of writing, the
exact relationships betweenmany key events in this cycle remain
to be defined, but what is known suggests that group 1 HDM
allergens are, by means of their proteolytic activity, the ignition
keys of fundamental innate responses. Consequently, novel mo-
lecular entities which inhibit the proteolytic activity of group
1 HDM allergens affect a broad spectrum of events relevant to
allergy initiation and maintenance (Zhang et al., 2018).
Through its interstitial prothrombinase activity, Der p 1 en-
ables the canonical activation of protease-activated receptor-1
(PAR-1) and PAR-4 by thrombin in a manner consistent with the
formation of a ternary complex of thrombin with receptor hetero-
oligomers (Chen et al., 2017) (Table 2). This is the beginning of a
regenerative cycle (Fig. 2A) from which key outputs are reactive
oxygen and nitrogen species. Although natural mixtures of HDM
allergens contain both serine and cysteine proteases, with the
former as candidates for the activation of PAR-2, potent and
selective inhibitors ofDerp1attenuate theproduction of virtually
all of the reactive species, suggesting that it is the major
component within the repertoire of the allergen mixture re-
sponsible for their generation. That PAR-2 cleavagemakes only a
minor contribution is indicated by the small effects of either its
pharmacologic antagonism or silencing by small interfering RNA
(siRNA). Probe studies with a DNA-binding triphenylphospho-
niumanalog of dihydroethidium indicate that at least someof this
generation occurs in mitochondria through a two-electron re-
duction of oxygen, and this establishes the basis for amechanism
for the upregulation of cytokine production through well charac-
terized mechanisms, notably those dependent on the transcrip-
tion factornuclear factorkB (Zhanget al., 2016;Chen et al., 2017).
under control conditions (circles), after stimulation by mixed HDM allergens (triangles), or after allergen stimulation in the presence of an allergen delivery
inhibitor (squares). (F) Initial rates of ROS formation derived from rhodamine formation in (E). (G) Silencing of TLR4 expression by siRNA attenuates
intracellular ROS generation evoked by mixed HDM allergens in calu-3 cells. Data for transfected control cells (con) and nontransfected cells are shown for
completeness. (H) Concentration-dependent inhibition of intracellular ROS formation by TAK-242 (an inhibitor of the association between TLR4 and the
signaling adapter proteins TIRAP and TRAM) in calu-3 cells stimulated bymixedHDMallergens (circles) or Der p 1 (triangles). The bar chart depicts the rate of
ROS formation (dihydrorhodamine oxidation) in unstimulated cells or in the presence of allergen activation. (I) Gene silencing of the production of the a-chain of
fibrinogen inhibits ROS generation bymixedHDMallergens. For (E–H), all data are shown as themean6S.E. with n = 4–8. *P, 0.001 vs. vehicle (veh); **P,
0.001 vs. HDM; †P, 0.05 vs. nontransfected HDM control. HDM 0.1, 1 refer to a natural mixture of allergens containing 0.1 or 1 mg ml21, respectively. Further
methodological details concerning the studies in (C–I) are available (Zhang et al., 2016, 2018), and these form the basis of previously unpublished or recomposited
data shown here. RFU, relative fluorescence units.
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Fig. 2. (A) The prothrombinase activity of Group 1 HDM allergens stimulates intracellular ROS formation in airway epithelial cells through an ATP and ADAM
10–dependent regenerating cycle initiated by the canonical cleavage of PAR-1 andPAR-4. The formation of endogenous ligands for TLR4plays a key permissive role
in this process because silencing of receptor expression or prevention of TLR4 interactions with intracellular adapter proteins blunts ROS formation. This signaling
cycle receives convergent stimulatory inputs from viral RNA sensors (TLR3/MDA-5/RIG-I/TLR7) upstream from the gating of pannexons by myosin motors. ROS
provide transcriptional regulation of gene expression through multiple mechanisms. Direct formation of thrombin by group 1 HDM allergens (prothrombinases)
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Reactive oxidant species activate transcription factors and induce
histone modifications favoring the induction of proallergic cyto-
kines, whereas through direct transformation of proteins, they
activate mitogen-activated protein kinase and the signal trans-
ducer and activation of transcription pathways which are
implicated in allergy and asthma (Comhair and Erzurum, 2010;
van Rijt et al., 2017). Other studies have provided direct evidence
of DNA damage resulting from HDM exposure in mice and
human lung cells, mirroring underlying events observed in
asthma (Chan et al., 2016).
Group 1 HDM Allergens, Pannexon Gating, and ATP
Release. Downstream from theDer p1–dependent activation of
PAR-1/4 lies the opening of pannexonswhich, inter alia, result in
the extracellular release of ATP (Fig. 2A; Table 2). These
pannexons are assembled from pannexin-1, and the release of
ATP operates as an innate alarm mechanism by signaling
through P2X7, P2Y2, and, to a lesser extent, P2Y4 receptors,
leading to the activation of A disintegrin and metalloprotease
10 (ADAM 10) and eventuating in the production of reactive
oxygen species (ROS). The recruitment of ADAM 10 into this
cycle is notable in that its other actions—namely, promoting
IgE synthesis through its cluster of differentiation 23 (CD23)
sheddaseactivity onB-lymphocytes (alsoadirect effect ofDerp1),
and recruiting dendritic cells, eosinophils, neutrophils, and
T cells through C-C chemokine ligand 20 (CCL20), CCL2,
CCL5, C-X-C motif chemokine ligand 8 (CXCL8), and CXCL16
release—signify a pleiotropic role in allergy, whereas its sheddase
action on E-cadherin of adherens junctions suggests an augment-
ing role in dysregulation of epithelial barrier permeability (Schulz
et al., 1995; Gough et al., 2004; Weskamp et al., 2006; Inoshima
et al., 2011; Mathews et al., 2011; Post et al., 2015) and the
promotion of epithelial-mesenchymal transition (EMT). However,
in airway epithelial cells responding to HDM allergens, it also
appears that ADAM 10 initiates further conversion of prothrom-
bin to thrombin—indirectly, directly, or both—but via events that
are significantly downstream from the prothrombinase activ-
ity of Der p 1. The ligand shedding activity of ADAM 10 is
Ca21-dependent (Nagano et al., 2004; Reiss and Saftig, 2009), so
an association with the opening of pannexons, which are perme-
able to both mono- and divalent cations, may be critical in its
activation. Recent studies from our laboratory indicate that
ADAM 8 may provide some support for ADAM 10 in this cycle,
suggesting an analogous relationship to that involved in CD23
shedding, where ADAM 10 is the constitutive sheddase whose
action can be duplicated, if necessary, by ADAM 8. The endoge-
nous production of thrombin activated by ADAM 10 and ADAM
8 is required for the generation of reactive signaling species, which
led us to consider what the further downstream consequences of
these reactions might be.
Group 1 HDM Allergens and Toll-Like Receptor 4
Ligation. Revealingly, we found that effective blockade of ROS
formation occurred by siRNA silencing of Toll-like receptor 4
(TLR4) or pharmacologic inhibition of its interaction with
the adapter proteins TIRAP and TRAM by ethyl-(6R)-6-(N-
(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate
(TAK-242) (Zhang et al., 2018). Attenuation of responses by a Der
p 1 inhibitor shows that this activation of TLR4 requires Der p 1
and is independent of ligation by bacterial lipopolysaccharides
(LPS), the archetypal agonists of this receptor (Zhang et al., 2018).
Although LPS is present in house dust and HDM allergen
mixtures, LPS is only weakly effective in triggering ROS produc-
tion, at least in healthy airways, because of a deficiency in the
myeloid differentiation protein-2 (MD-2) co-receptor and the
polarized basolateral distribution of TLR4, which protects it from
nuisance triggering by exogenous signals. However, TLR4 is
activated by a range of putative endogenous ligandswhich include
fibrinogen and its cleavage products (Hodgkinson et al., 2008;
Erridge, 2010; Yuet al., 2010;Millien et al., 2013;Cho et al., 2017).
Airway epithelial cells secrete fibrinogen from their basolateral
aspect in a vectorial, microtubule-dependent manner and are one
of few extrahepatic sites where all three component chains of the
protein are expressed (Guadiz et al., 1997). This leads to the
possibility that fibrinogen cleavage products are the agencies by
which Der p 1–dependent TLR4 activation is achieved, although
ensemble participation of other TLR4 ligands should not be
excluded. The involvement of fibrinogen is indicated by attenua-
tion of responses in airway epithelial cells in which expression of
the FGA gene, which encodes the a-chain of the protein, has been
silenced by siRNA (Fig. 2B). The Der p 1–dependent activation of
TLR4 is, therefore, a consequence of the chain of signaling events
initiated by its activation of PAR-1 and PAR-4, and the TLR4-
dependent action of selective P2Y2R or P2X7R agonists suggests
that the coupling of TLR4 ligation to ROS production occurs
downstream from the gating of pannexons (Zhang et al., 2018).
Discovery of a linkage between Der p 1 and TLR4 is of
considerable interest because TLR4 expressed on airway
epithelial cells is an indispensable requirement for the devel-
opment of allergic sensitization to HDM allergens (Hammad
et al., 2009). Ligation of TLR4 leads to an activation of cells by
IL-1a and the release of granulocyte macrophage colony-
stimulating factor and IL-33 (Willart et al., 2012), the latter
being a bioactivation target of the Der p 1 enzyme also (Cayrol
et al., 2018) (Table 2). The importance of TLR4 and this triad of
cytokines is demonstrated by depletion of the receptor or
cytokine neutralization preventing allergic responses
(Hammad et al., 2009; Willart et al., 2012). Until the discovery
of how Der p 1 leads to TLR4 activation, the mechanisms
offered to account for the indispensability of TLR4 were: 1) the
presence in PAR-2 of a potential Toll/interleukin-1 receptor
domain which might bind to myeloid differentiation primary
response 88 (MyD88) in the TLR4 signaling complex, which
regulates early nuclear factor kB–dependent gene transcrip-
tion (Barrett et al., 2009); and 2) the similarity between group
2 HDM allergens and MD-2, which functions as a co-receptor
protein in the response to LPS (Eisenbarth et al., 2002;
Trompette et al., 2009). A structural feature linking the group
appears tobe functionally compartmentalized fromtheADAM10–dependent generation of prothrombinbecausePAR-1,PAR-4, andpannexin-1 are required for the
former. Although the underlying reasons for this dichotomy are not established, it may reflect poor accessibility of apically generated ligands to TLR4 in a polarized
epithelium. The figure was revised and updated with added mechanistic details from the scheme originally published by Zhang et al. (2018). (B) Gene silencing
production of thea-chain of fibrinogen in calu-3 airway epithelial cells inhibitsROSgeneration activatedby ligation of P2X7 (29(39)-O-(4-benzoylbenzoyl)adenosine 59-
triphosphate, BzATP) or P2Y2 (uridine-59-tetraphosphate d-phenyl ester tetrasodium salt,MRS2768) receptors. *P, 0.001 vs. vehicle (veh) controls; **P, 0.001 vs.
stimulated cells (nontransfected and transfection control, con). (C) Gene silencing of ADAM10 or ADAM8 attenuates ROS production by calu-3 cells stimulated by
mixedHDMallergens containingDer p 1 at 1mgml21. *P, 0.001 vs. veh controls; †P, 0.001 vs. stimulated cells; ‡P, 0.001 vs. veh controls. Data in (B andC) are
shownas themean6S.E. (n=8). Thenewdata shown in (B andC) usedmethodswhichhave beenpublished elsewhere (Zhang et al., 2016, 2018). EGFR, epidermal
growth factor receptor; RFU, relative fluorescence units.
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2 HDM allergens with MD-2 is the presence of a large
hydrophobic pocket capable of binding lipophilic ligands such
as LPS. The attraction of this MD-2 mimicry by group 2 HDM
allergens is that it might provide a means to compensate for a
relative deficiency of MD-2 in airway epithelial cells and offers a
mechanistic connection to LPS which is implicated in allergy
development under certain conditions. However, MD-2 mimicry
suffers limitations as a central initiator mechanism, not least in
failing to accommodate the cellular distribution of TLR4 in a
healthy-airway epithelium. Unlike group 1 HDM allergens,
those of group 2 neither initiate ROS production nor have a
direct effect on epithelial barrier properties when protease
contamination is rigorously excluded. Indeed, studies on the
transepithelial disposition of Der p 2 show that significant
permeation occurs only in the presence of proteolytically active
group 1 allergens and can be prevented by a novel Der p 1
inhibitor of high potency. Moreover, inhibition of Der p 1 pro-
teolytic activity prevents allergic sensitization in mice (Gough
et al., 1999, 2001; Zhang et al., 2009; Robinson et al., 2012), an
effectwhich is hard to reconcilewith the indispensability of TLR4
being solely reliant on MD-2 mimicry. Our data provide an
alternate rationale where the decisive event is thrombin forma-
tion by the direct prothrombinase activity of group 1 HDM
allergens which, in turn, facilitates the formation of endogenous
TLR4 ligands in the airway epithelium through activation of an
additional endogenous prothrombinase (Zhang et al., 2016,
2018). The identities of these endogenous TLR4 activators
remain unclear, but gene silencing of any one of the three
component chains of fibrinogen abrogates ROS production by
Der p 1 in human airway epithelial cells, although other ligands
appear to participate too (Fig. 2B and our unpublished data).
Significantly, selective inhibitors of Der p 1 provide effective
inhibition of all these events (Zhang et al., 2018). It is evident
from the foregoing that the airway epithelium is the cellular host
of a sophisticated signaling nexus which combines the physical
delivery of allergen to antigen-presenting cells, and thereby
T-lymphocytes, with the creation of a signaling environment
which transduces the progression from innate to acquired
immunity with an allergic polarization.
Signaling Convergence Between Group 1 HDM
Allergens and Viral RNA Sensors. A fascinating aspect of
this HDM allergen–dependent route to TLR4 ligation and the
production of reactive intermediates which regulate gene expres-
sion is that the signaling mechanisms converge with cellular
responses initiated by ligation of the viral RNA sensors TLR3 and
TLR7 (Fig. 2A; Table 2) (Zhang et al., 2016, 2018). The point of
convergence lies upstream from the myosin motor2dependent
gating of pannexons and ATP release (Zhang et al., 2018). In
allergic asthma, disease exacerbations arise from interactions
between allergens and respiratory viruses (principally rhinovirus,
respiratory syncytial virus, and influenza), so the identification of
a nexus linking these stimuli provides new insight into how these
exacerbations are precipitated. Interestingly, given the regenera-
tive cycle which underlies this production of ROS, activation of
PAR-1 contributes to the pathogenicity of influenza A, and PAR-1
and TLR3 are both upregulated by infections caused by respira-
tory viruses (Groskreutz et al., 2006; Antoniak et al., 2013).
Thrombin and ATP: Innate Effector-Perpetuators in
Allergy. It has been known for some time that concentrations of
thrombin in airway surface liquid are elevated in asthma to levels
which are capable of driving cell proliferation, and they are also
raised following respiratory virus infection (Terada et al., 2004).
Whereas some thrombin may result from tissue-repair mecha-
nisms activated by inflammation,more recent data suggest that it
also functions as an innate strategic initiator and an effector-
perpetuator of allergy through its direct generation by inhaled
Der p 1 (Zhang et al., 2016). Similarly, ATP is present in elevated
concentrations in bronchoalveolar lavage fluid in asthma (Müller
et al., 2011), consistent with the allergen-dependent gating of
pannexons. In addition to triggering ROS generation, it initiates
the release of IL-33, which is pivotal in the orchestration of
responses mediated by ILC2 cells and promotes a Th2 bias in
dendritic cells (Idzko et al., 2007; Müller et al., 2011). The actions
of ATP extend downstream from these events and additionally
activate mast cells, eosinophils, and cause dyspnea (Schulman
et al., 1999; Basoglu et al., 2005). In keeping with the foregoing,
novel Der p 1 inhibitors which abrogate thrombin generation and
pannexon-dependent ATP release also attenuate eosinophil re-
cruitment, inhibit the release of IL-33andTSLP, and impair acute
allergic bronchoconstriction (Newton et al., 2014 and our un-
published data). Their ability to reduce IL-33 production in the
airways removes a critical component of innate immune signaling
which directs the development and persistence of allergic sensi-
tization and some of its key pathophysiologic features.
Activation of PAR-2 and Mas-Related G-Protein–
Coupled Receptor X1. The discovery of PARs naturally
prompted speculation that they could be receptors for protease
allergens, especially those, like the group 3 and group 6 HDM
allergens, with substrate preferences similar to canonical
activators of these receptors. That group 1 HDM allergens
would interact with one or more of these receptors was
assumed to occur through an example of biased agonism.
The ability of HDM allergen extracts and purified allergens to
stimulate cytokine (e.g., IL-6, IL-8, CCL11, granulocyte
macrophage colony-stimulating factor) release from airway
epithelial cells or keratinocytes in a manner which paralleled
the effects of PAR agonist peptides reinforced this view,
especially highlighting PAR-2 as an important molecular
recognition system for protease allergens with a central
mechanism in disease (King et al., 1998; Kato et al., 2009).
However, subsequent investigations suggested that an asso-
ciation of PAR-2 with asthma and other allergic conditions is
complex. Illustratively, in mouse models of HDM sensitization,
it is dispensable (Asokananthan et al., 2002; Adam et al., 2006;
Post et al., 2014), and in some disease models, PAR-2 activation
dampens rather than escalates inflammation (De Campo and
Henry, 2005; Ebeling et al., 2005); in the case of group 1 HDM
allergens, there are conflicting accounts of whether PAR-2
cleavage is an activation signal at all. Furthermore, the discovery
that Der p 1 is a prothrombinase which initiates the PAR-1- and
PAR-4–dependent ligation of TLR4 introduces a significant new
dimension to how protease-mediated signaling promotes and
maintains allergy.
An aspect of chronic asthmawhichmay linkDer p 1 and PAR-2
is airway remodeling and EMT, in which transforming growth
factor-b is a key element (Hackett, 2012). Group 1HDMallergens
activate latent transforming growth factor-b and promote EMT
characterized by a PAR-2 and epidermal growth factor receptor–
dependent reduction of E-cadherin expression by epithelial cells
(Nakamura et al., 2006; Heijink et al., 2010a,b; Frisella et al.,
2011), which in turn is a stimulus for the upregulation of CCL17
and TSLP (Heijink et al., 2007). As described earlier, Der p 1
activates PAR-4, which itself is implicated as an initiator of EMT,
and the ensuing cycle which leads to ROS formation involves
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ADAM 10, a key sheddase of E-cadherin (Ando et al., 2007;
Inoshima et al., 2011; Chen et al., 2017).
Attention has also turned to the activation of other receptors
in conjunction with PARs. Data have been obtained to show that
Der p 1 activation of the orphan receptor Mas-related G-protein
coupled receptorX1 (MRGPRX1) from themas-relatedG-protein–
coupled receptor family contributes to PAR-2–dependent cytokine
release from cultured human airway epithelial cells (Reddy and
Lerner, 2017), although the relevance to allergy remainsuntested.
However, a possible link between Der p 1 and MRGPRs is
intriguing because of their expression in sensory neurons and
mast cells. The latter degranulate in response to the proteolytic
action of Der p 1 through an uncharacterized mechanism in-
dependent from IgE cross-linkage (Machado et al., 1996). In the
context of MRGPRs (and PARs) transducing the nociception of
pain and itch, the ability of a protease to activate such physiologic
responses is well established, not least through the use of spicules
from pods of the cowhage plant (Mucuna pruriens), which contain
the cysteine protease mucunain, as an experimental stimulus in
human volunteers (Wolff and Goodell, 1952; Broadbent, 1953;
Shelley and Arthur, 1955; Reddy et al., 2008). Others will be
aware of mucunain’s efficacy at inducing a burning pain by prank
exposure to “itching powder,” a favorite product of novelty shops.
One unexpected feature which became quickly evident in early
studieswith cowhage is that its ability to induce pruritis is heavily
reliant on histamine release (Broadbent, 1953), suggesting that
the concept of pseudoallergic, protease-dependent mast cell
activation should be revisited in the context of contemporary
receptor biology and innate immunity.
Group 1 HDM Allergens and Deficits in Antioxidant
Defense. One of the long-standing enigmas of allergy is
why environmentally pervasive inhalant allergens evoke
sensitization in only a subset of the exposed population. The
generation of ROS by airway epithelial cells as an innate
response to group 1 HDM allergens suggests a scheme to
account for some of this difference in susceptibility. It is well
established that a deficit in enzymatic and nonenzymatic
antioxidant defenses is common in asthma (Sackesen et al.,
2008; Comhair and Erzurum, 2010). Some of these are
genetically determined (Fryer et al., 2000; Spiteri et al.,
2000; Mapp et al., 2002), whereas others may arise conse-
quentially from the development of disease. These deficits
are exacerbated by the pathogenetic upregulation of oxi-
dant production, such as the induction of NADPH oxidase
subunits by cytokines. HDM allergen extract increases the
selective expression of DUOX-1 in human airway epithe-
lial cells, and this is correlated with enhanced release of
hydrogen peroxide and IL-33 (Hristova et al., 2016). In
asthma, allergen exposure increases DUOX-1 expression by
the nasal epithelium, and neutrophil-derived ROS produc-
tion by Der f 1 is greater than in controls without asthma
(Fukunaga et al., 2011). The enhancement of ROS pro-
duction by certain allergens may itself be a further factor in
promoting the allergenicity of other exogenous proteins
through carbonyl adduction to form reactive aldehydes
which can direct a Th2 proliferative bias in T-lymphocytes
(Moghaddam et al., 2011).
A key role for oxidant/antioxidant balance in shaping the
development of allergy is suggested by compelling evidence
from disease models. In mice, the cysteine protease papain
promotes sensitization through mechanisms involving oxida-
tive stress (Tang et al., 2010), and partial inhibition of
protease activity blunts the capacity of HDM allergen extract
to induce allergic inflammation (Utsch et al., 2015). Corre-
spondingly, mice deficient in themaster antioxidant regulator
nuclear factor (erythroid-derived 2)-like 2 (Nrf2), or which
are unable to upregulate it, develop enhanced responses
to ovalbumin or HDM allergens (Rangasamy et al., 2005; Wil-
liams et al., 2008; Li et al., 2013; Utsch et al., 2015). Similarly,
glutathione depletion exacerbates airway hyper-reactivity
and inflammation (Nadeem et al., 2014). Consistent with this
theme, an Nrf2 activator protected against IL-33 release and
allergic responses (Uchida et al., 2017), whereas overexpres-
sion of Nrf2 enhanced the expression of ZO-1, occludin, and
E-cadherin in the airway epithelium (Comhair et al., 2001).
Antigen-Presenting Cell Recruitment. Accumulation
of antigen-presenting cells at mucosal surfaces and their
departure for interaction with T-lymphocytes is a strategic
conduit linking innate and acquired immune responses to
allergens. This is demonstrated by the observations thatHDM
allergen exposure recruits antigen-presenting cells to lung
[dendritic cells (DCs)] and skin (Langerhans cells) through the
agency of chemokine release (CCL2, CCL5, CCL20, and
CXCL10) by epithelial cells (Pichavant et al., 2005), and that
humanized SCID mice reconstituted with monocyte-derived
DCs from patients with atopic asthma are predisposed to
develop immune responses with a Th2 polarization (Hammad
et al., 2002). Transcriptomic analysis in HDM allergen–
exposed airway epithelial cells or clinical airway specimens
suggests that chemokines directed against antigen-presenting
cells constitute part of an upregulated core gene repertoire
(Vroling et al., 2008a,b). Both CCL2 and CCL20 have been
proposed as pivotal in the increased steady-state numbers of
DCs in the bronchial mucosa of patients with asthma, with a
notable increase in Der p 1–dependent CCL20 release in
airway samples in atopic asthma (Pichavant et al., 2005). A
role for CCL20 in response to HDM allergens is replicated in a
mouse model where its release is TLR4-dependent (Hammad
et al., 2009). CCL20 is a ligand for C-C chemokine receptor 6
(CCR6), which is expressed on Langerhans cell–like precur-
sors of conventional DCs that are associated with inflamma-
tory events. In mice deficient in CCR6, allergic pulmonary
responses are attenuated due to impaired migration of DCs
(Lukacs et al., 2001). In contrast to HDM allergen responses,
signaling via the CCL20/CCR6 axis does not occur with
ovalbumin (Robays et al., 2007), which requires the collateral
priming effects of the proteolytic activity of Der p 1 or another
adjuvant for the development of robust IgE responses (Gough
et al., 1999, 2001; Fattouh et al., 2005; Zhang et al., 2009).
Release of CCL20 from human airway epithelial cells by HDM
allergen extracts also occurs through a b-glucan–dependent
route. This mechanism is protease- and TLR4-independent
but involves Syk activation, suggesting that it might be
mediated through the C-type lectin receptor, dectin-1
(Nathan et al., 2009). Other work has suggested a role for
b-glucan–dependent, TLR2-mediated signaling by HDM al-
lergen extracts in the nasal mucosa (Ryu et al., 2013). Similar
to chitins [b-(1,4)-poly-N-acetyl-D-glucosamine polymers]
which also ligate dectin-1 (Lee et al., 2011), b-glucans are
extraneous factors in HDM culture extracts and components,
from multiple sources, of environmental house dust, so this
activation of chemokine production by multiple mechanisms is
anticipated as a multilayered reinforcement of allergic polariza-
tion. Although these observations suggest the importance of
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CCL20/CCR6 signaling in the allergic recruitment of DCs, the
pattern of chemokine and receptor activation seems likely to be
more complex given that the high phenotypic plasticity of antigen-
presenting cells provides them with a versatile repertoire of
delegated effector roles. For this reason, selective intervention at
targets within this particular checkpoint in the initiation and
maintenance of allergy may be of variable benefit compared
with other options. Illustrating the difficulty in validating
CCL20/CCR6 as a discrete, primary target pairing, CCL2,
CCL5, and CXCL10 chiefly act via ligation of CCR1, CCR2,
CCR5, and CXCR3 found on DCs of monocyte derivation, and of
these combinations, the interaction of CCL2-CCL2R is particu-
larly interesting in allergy development because CCR21Ly6chi
monocytes are precursors of inflammatory CD11b1 DCs found
in allergy (Robays et al., 2007; Hammad et al., 2009).
Although antigen-presenting cell recruitment and activa-
tion may be driven primarily through signaling events
triggered by HDM allergens in the airway epithelium, the
allergens must also have direct interactions with antigen-
presenting cells, and these have been the subject of some
scrutiny in the context of protease-dependent activation and
programming of Th2 polarization. One approach has been to
use in silico prospecting for potential substrates of Der p 1
among the cell surface proteins found on dendritic cells,
resulting in identification of C-type lectin receptor dendritic
cell–specific intercellular adhesion molecule 3–grabbing non-
integrin (DC-SIGN) and its homolog DC-SIGN receptor as
potential substrates of Der p 1 (Table 2). In support of this,
recombinant DC-SIGN and DC-SIGN receptor are cleaved by
Der p 1 in vitro (Furmonaviciene et al., 2007). DC-SIGN
expression is reduced in DCs exposed to Der p 1, although it is
hard to ascertain how much of this disappearance is due to
proteolysis or to protease-independent endocytosis (Kauffman
et al., 2006; Furmonaviciene et al., 2007).
The challenge of devising a successful antigen presentation
checkpoint intervention is further demonstrated by another
potential target of Der p 1 in DCs (Table 2). Der p 1 causes a
downregulation of indoleamine 2,3-dioxygenase inHDM-sensitive
individuals (Maneechotesuwan et al., 2009). Indoleamine 2,3-
dioxygenase catalyzes the conversion of tryptophan to kynurenine
and causes immunosuppression through a combination of trypto-
phan depletion (which activates a sequence of events through
induction of general control nonrepressed 2 kinase) and the direct
cellular effects of kynurenine and other tryptophan metabolites
(Johnson et al., 2009). Consequently, downregulation of the
enzyme byDer p 1 is a potentially interestingmechanism leading
to the breaking of immune tolerance and the development and
maintenance of sensitization. Indoleamine 2,3-dioxygenase activ-
ity is particularly important in antigen-presenting cells, al-
though there is notable heterogeneity in its significance in
different DC subsets, especially between conventional DCs and
plasmacytoid DCs (Harden and Egilmez, 2012). The success of
attempts to induce tolerance to an allergen by manipulation of
indoleamine 2,3-dioxygenase activity may, therefore, depend on
which subset(s) of DCs is most relevant. It should also be noted
that chronically stimulating indoleamine 2,3-dioxygenase activity
may not be generally beneficial because of the inherent risks
associated with a concomitant attenuation of routine immune
surveillance for pathogens and tumors (Muller et al., 2008;
Harden and Egilmez, 2012). For these and other reasons, we
preferred a different approach focused on the allergen rather than
innate host checkpoints.
Allergen Delivery Inhibitors
The strong causative association of serodominant group
1 HDM allergens with major allergic diseases makes them a
compelling target in the search for unprecedented interven-
tions intended to modify the basic immunologic events that
are responsible for the development of disease. As outlined in
the earlier sections, and summarized by the actions listed in
Table 2, understanding how their proteolytic activity drives
these sentinel events provides encouragement that inhibitors
of this proteolytic activity offer the prospect of disease
modification. The chemical design challenge associated with
this unprecedented mechanism was significant, and the
identification of developable candidates necessitated the
rigorous pursuit of a clear vision of the required attributes,
some of which would be deemed an unusual focus in most
early-stage discovery research. Given the similarity of group
1HDMallergens as proteases, this enabled us to useDer p 1 as
the archetypal template for inhibitor design. We call this new
class of drugs “allergen delivery inhibitors” to reflect that they
interfere with the ability of HDM allergens to engage with
antigen-presenting cells. As will now be evident, this process
of “delivery” is a combination of biophysical events in in-
tercellular junctions and the creation of a complex molecular
signaling pathway which leads from innate immunity to the
acquisition and persistence of allergic sensitization.
Our approach to Der p 1 inhibitor design was informed by
the fact that the targets are inhalant allergens, and prevent-
ing their effects at the site of initial impaction in the lungs
would be advantageous. With a nonhuman inhaled target, the
interaction with an inhibitor has no requirement for cell
permeation, which, in combination with properties designed
to minimize systemic exposure, means a significant opportu-
nity to mitigate safety risks in chronic therapy. There are
several device options for the delivery of drugs by inhalation,
viz. nebulizer, metered dose inhaler, and dry powder inhaler
(DPI). We elected to pursue compounds that would be
compatible with DPI delivery, with the expectation that this
would bring confidence for usage in other devices. Delivery by
DPI imposes a burden on chemical design and pharmaceutics
because it demands nonhygroscopic, stable, crystalline com-
pounds which can produce particles of consistent size that will
distribute uniformly to the site of action in the lung, in
addition to embodying the pharmacologic profile for target
selectivity, potency, safety, and duration of action.
Opening explorations of Der p 1 inhibitor design were based
around the introduction of inhibitory warheads into a modi-
fied peptide substrate sequence based on the scaffold peptide
VAJS. Contrary to the development of compounds for oral
delivery, it is usually advantageous for inhaled asthma drugs
to have poor oral bioavailability to minimize systemic expo-
sure and thus achieve a good safety profile. Therefore,
compounds which violate Lipinski “rules” provide interesting
freedoms for inhaled drug design which would not usually be
tolerated in other settings. A peptide template, with a high
proportion of hydrogen bond donors and acceptors in a flexible
scaffold, was therefore considered a useful departure point for
such an application. An exemplar derived from this scaffold is
aldehyde 1 (Fig. 3), but despite encouraging potency, it was
compromised by expectations of instability and nonspecific
reactivity. Surprisingly, somewarheads effective in the design
of cysteine peptidase inhibitors directed at other targets were
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found to be poor inhibitors of Der p 1, such as vinylogous esters
and sulfones elaborated from the scaffold of 1. Initial progress
in the search for potent Der p 1 inhibitors was made with the
identification of a series of acyloxymethyl ketones exemplified
by 2, 3, and 4 (Fig. 3). Docking of 3 in Der p 1.0105 (Protein
DataBank: A2S8) suggested that the norleucine side chain
makes hydrophobic interactions with the P1 pocket while the
carbonyl initially forms a reversible covalent bond with C114,
and the NH a hydrogen bond with Y249 (Newton et al., 2014).
Consistent with the mechanism of inhibition for acyloxy-
methyl ketones, C114 subsequently migrates to displace the
acyl group, forming an irreversible covalent bond with the
inhibitor. The amino and carbonyl groups of alanine hydrogen
bond with D154, and the preference for compact groups at P2
arises because of I156. The side chain of valine makes a
hydrophobic interaction with the P3 pocket, and the benzoyl
Fig. 3. (A) Inhibitors of Der p 1 identified in early discovery research. Activity for the reversible inhibitor aldehyde 1 is expressed as the inhibition constant,
whereas data for the acyloxymethyl ketones with irreversible action are expressed as second-order inhibitor rate constants. Measurements were performed as
described by Newton et al. (2014) and the online supporting information, https://pubs.acs.org/doi/suppl/10.1021/jm501102h and https://pubs.acs.org/doi/suppl/
10.1021/jm501102h/suppl_file/jm501102h_si_001.pdf, using (3S,6S,9S,12S,15S,18S)-1-(2-aminophenyl)-9-butyl-18-carbamoyl-15-(4-hydroxy-3-nitrobenzyl)-12-
(hydroxymethyl)-3-isopropyl-6-methyl-1,4,7,10,13,16-hexaoxo-2,5,8,11,14,17-hexaazaicosan-20-oic acid as substrate. (B and C) Docking of compound 3 in the
substrate-binding groove of Der p 1.0105 shown, respectively, as surface representation and simplified stick view revealing hydrogen bonding interactions with
Derp 1. (D) General mechanism for irreversible inhibition of Der p 1 using acyloxymethyl ketone 3 as exemplar.
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capping group forms hydrophobic p-stacking associations
with tyrosine residues. Although docking analysis provided
useful information to guide subsequent chemical design, the
acyloxymethyl ketones, per se, lack developability, primarily
through concerns about their irreversible inhibition of the
target. Therefore, the challenge was to identify functional
groups which would enable the creation of compounds whose
target inhibition was reversible while maintaining the bene-
fits of slow off-rate. To this end, we investigated a series of
inhibitors which were capable of forming a reversible covalent
bond with C114. An advance toward this goal was a series
of amino ketones which demonstrated the achievability of
Fig. 4. (A) Transition from irreversible to reversible binding mode inhibitors of Der p 1 by modification of the cysteine binding motif and identification of
pyruvamide 7. Inhibitor characteristics were determined as disclosed byNewton et al. (2014) and the online supporting information, https://pubs.acs.org/
doi/suppl/10.1021/jm501102h and https://pubs.acs.org/doi/suppl/10.1021/jm501102h/suppl_file/jm501102h_si_001.pdf, using (3S,6S,9S,12S,15S,18S)-1-
(2-aminophenyl)-9-butyl-18-carbamoyl-15-(4-hydroxy-3-nitrobenzyl)-12-(hydroxymethyl)-3-isopropyl-6-methyl-1,4,7,10,13,16-hexaoxo-2,5,8,11,14,17-
hexaazaicosan-20-oic acid as substrate. (B) General mechanism for reversible inhibition of Der p 1 using amino ketone 5 as exemplar.
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incorporating a reversible inhibitormotif into a scaffold, which
offered good prospects for optimization. However, despite
initially encouraging progress, it proved impossible to in-
crease potency beyond that of compound 5 (Fig. 4). This
activity was deemed insufficient when rated against a com-
pound developability profile whose potency requirements had
been defined from empirical estimates of target exposure in
humans and the need to be mindful of device dosage practi-
calities (Newton et al., 2014).
Reassurance that an uplift in potency could be achieved in a
reversible inhibitor was provided by 6 (Fig. 4), albeit using a
functionality of limited developability. A pursuit of alternative
groups led to the identification of a series of pyruvamides, such
as 7 (Fig. 4), which became the focus for detailed exploration
(Newton et al., 2014). The inhibitory potency of 7 against the
Der p 1 target is compatible with the declared profile for
development, but it is not optimized with respect to properties
which influence the persistence at the site of action or its
selectivity over obvious off-target nuisances. As a design tool
for optimization, a computational model was created based on
the structure of Der p 1.0105 and on the structures of peptidic
inhibitors bound to cathepsin K. Compound 7 was built
and energy-minimized in the substrate-binding groove of
Der p 1 with the electrophilic carbonyl of the pyruvamide
moiety orientated to interact with C34 and the peptide
backbone aligned to follow a trajectory similar to that of the
other peptidic inhibitors. As shown in Fig. 5, this revealed
interactions between the amide carbonyl of the pyruvamide
and the backbone NH of C114, the NH of the P1 subunit, and
the carbonyl of Y249 and the formation of a donor:acceptor pair
with the backbone carbonyl and NH of D154. This tool enabled
the prioritization of chemical design decisions which were
rigorously explored by iterative rounds of synthesis and
screening, details of which are provided elsewhere (Newton
et al., 2014). Counterscreening against Der f 1 provided
confidence that compounds designed usingDer p 1 as template
were similarly active in other HDM species.
Pursuant to producing compounds which were efficacious
against real-life allergen exposure and not just a single purified
allergen, a range of in vivo studies were undertaken to establish
confidence indevelopability (Newton et al., 2014).An example for
compound 8 is shown in Fig. 6. Eosinophils in bronchoalveolar
lavage fluid were chosen as a readout in these studies because
elevations in blood eosinophils and eosinophil recruitment to the
airways are hallmark features of allergic asthma in many
patients and correlate with disease severity. Importantly, these
animals were sensitized and challenged with the complete
palette of house dust mite allergens in a naturally derived
mixture and not simply with the purified target allergen. As
illustrated, a single inhaled dose of the compound produced a
striking reduction in eosinophil recruitment after acute allergen
challenge in an IgE-dependent model. This is an interesting
result because our expectation is that ADIs will exhibit greatest
benefits against underlying IgE-independentmechanismswhich
drive the acquisition and persistence of disease. Thus, even in a
model where a strong IgE response existed and allergen
challenge comprised a full palette of HDM allergens, targeting
only the Der p 1 component produced a result suggesting useful
efficacy (Newton et al., 2014).
To further explore the chemical features necessary for a
persistence of effect, we evaluated a subset of potent com-
pounds which were stable in contact with airway cells. To
neutralize additional variables created in IgE-dependent
challenge models, we electively conducted investigations
using animals which were HDM allergen–naïve because
aerosol challenge with Der p 1 or HDM allergen mixtures
results in eosinophil recruitment to the airways in the absence
of HDM sensitization (Newton et al., 2014). The kinetics of this
IgE-independent innate response are indistinguishable from
Fig. 5. Docking model of compound 7 bound to the active site of Der p
1.0105. Procedural details are presented by Newton et al. (2014), https://
pubs.acs.org/doi/suppl/10.1021/jm501102h.
Fig. 6. (A) Quaternaryammoniumcompound8. (B)Effect ofasingleaerosolized
dose of 8 (18 nmol/kg) on the recruitment of eosinophils to the airways following
aerosol challenge with mixed HDM allergens in sensitized brown Norway rats.
The compound was administered 2 hours prior to HDM allergen by means of a
Penn-Centuryaerosolizer (Penn-Century,Philadelphia,USA).Dataaredisplayed
as means 6 S.E. in groups of 10 animals. *P , 0.05 vs. vehicle (veh) challenge;
**P , 0.05 vs. HDM without test substance pretreatment; veh, vehicle. Full
details of treatment protocols are provided byNewton et al. (2014) and the online
supporting information, https://pubs.acs.org/doi/suppl/10.1021/jm501102h and
https://pubs.acs.org/doi/suppl/10.1021/jm501102h/suppl_file/jm501102h_si_001.
pdf. BAL, bronchoalveolar lavage.
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Fig. 7. (A) Relationship between inhibitor polar surface area and log D7.4 for a subset of compounds used for the examination of in vivo efficacy. Symbols
depict ionization state at pH 7.4: neutral (purple circles), positively charged basic center (orange squares), and positively charged quaternary ammonium
(blue diamonds). (B) Percentage reduction in bronchoalveolar eosinophil counts 48 hours after challenge of nonsensitized rats with a natural mixture of
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sensitized animals, but the effect is smaller in magnitude.
Compounds selected for these studies spanned a range of log
D7.4 values and polar surface areas (Fig. 7). Better efficacy was
associated with lipophilicity, but good activity also existed in
quaternary ammonium compounds (e.g., 8, 14) (Newton et al.,
2014). As anticipated, the latter benefited from having low oral
absorption, thus restricting systemic exposure in a manner
which offers some advantages over alternate approaches where
deliberately promoting the biotransformation of absorbed drugs
can generate unexpected metabolic liabilities.
As the electrophilic pyruvamide motif has potential for
nonspecific interaction with suitable nucleophiles, it was
imperative to achieve selectivity over potential off-targets,
even though many of these are intracellular and thus in-
trinsically resilient to reaction compared with the facile
extracellular interaction with Der p 1. As already described,
the S3 pocket of Der p 1 is more capacious than in cathepsins,
and our screening campaign confirmed that the steric bulk in
this position increased selectivity while retaining potency on
target. Inspection of the structural model suggested that the
S2 pocket of Der p 1 was shallow compared with cathepsin B,
K, or S, and so with compact substituents at this position,
it was possible to obtain a useful balance of potency and
selectivity (Newton et al., 2014). As an aside, Blo t 1 exhibits a
similar feature at its putative S2 pocket, suggesting that
compounds designed against a template from a pervasive
HDM species may have characteristics which translate to
allergens from mites whose evolution has diverged to suit
niche environments. Once confidence in the contributions of
the P2 and P3 substituents were obtained, we explored greater
variation in the P4 and P9 groups, which pleasingly revealed
the feasibility of synthesizing compounds, such as 16–21, of
high inhibitory potency and good selectivity consistent with
developability (Fig. 8) (Newton et al., 2014).
We examined exemplars of optimized compounds in vivo
using a variety of readouts to establish confidence in efficacy
Fig. 8. Further optimization of the P4
(R) and P9 groups produces compounds
showing high target potency and intrinsic
selectivity over cathepsin B. Chemical syn-
theses and enzymatic activity assays
are described by Newton et al. (2014)
and the online supporting information,
https://pubs.acs.org/doi/suppl/10.1021/
jm501102h and https://pubs.acs.org/
doi/suppl/10.1021/jm501102h/suppl_file/
jm501102h_si_001.pdf.
HDM allergens following a single aerosolized dose of test substance administered 2 hours prior to allergen challenge. The percentage reduction was calculated
relative to vehicle-pretreated animals which underwent similar HDM allergen challenge. Test substances were administered at a drug:target ratio of 50:1 with
the exception of compound 11, tested at 15:1. Data are themean6S.E. with 10 animals per treatment group. *P, 0.001 comparedwithHDMchallenge control.
Column coloration depicts ionization state of test substance as in (A). (C) Structural information and potency data for compounds used in this study. Full
experimental details for chemical syntheses and biologic studies are provided byNewton et al. (2014) and the online supporting information, https://pubs.acs.org/
doi/suppl/10.1021/jm501102h and https://pubs.acs.org/doi/suppl/10.1021/jm501102h/suppl_file/jm501102h_si_001.pdf. BAL, bronchoalveolar lavage.
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and duration of protection. These studies confirmed the
structural features required for compliance with the exacting
candidate drug template and provided test data from which
clinical candidates could be selected (Newton et al., 2014). A
wider examination of the effects of ADIs in experimental
models reveals the potential for a fascinating spectrum of
effects in the clinic and a profile which is interestingly
differentiated from the current standard of care and other
entities in development for asthma (Fig. 9; Table 3). The
overall impression is of an intervention which has the breadth
Fig. 9. Predicted effects profiles for ADIs based on
preclinical discovery researchmodels (published and
on-file data). (A) Effects of HDM exposure in the
airways with a focus on innate immune responses.
(B) Example effects of HDMexposure in the presence
of ADI drug, with affected pathways grayed out.
GMCSF, granulocyte macrophage-colony stimulat-
ing factor.
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normally associated with corticosteroids. However, ADIs can
affect events which are not directly regulated by steroids, and
notably, their broad range of effects is achieved without
incurring penalties from nonspecific immunosuppression.
Pre-eminent in the readouts which show positive effects of
ADIs are those strongly associated with events identified by
experimental biology as being indispensable in allergy. Some
of the signaling entities which drive these indispensable
events are now the target of biologic therapies in development.
The ability to attenuate the same signals simultaneously by
means of an inhaled small molecule provides a superior option
with the potential for usage across a broader spectrum of
patients.
Concluding Remarks
From the earliest scientific investigations of allergy, the
causative link between allergens and the diseases they pro-
duce has attracted attention as a means of disease treatment.
The outstanding example of this is the pioneering work of
Freeman and Noon (1911), which led to the development of
allergen immunotherapy and attempted to tolerize the im-
mune system to a particular allergen. However, targets for
small-molecule interventions at the root cause level have been
nonobvious until recently, so the pharmacotherapy of allergy
adopted a different approach which exploited progress in the
identification of bioactive mediators and the elucidation of
effector mechanisms. The renaissance of innate immunity and
an increasing understanding of the molecular basis of aller-
genicity now creates the first opportunity for pharmacother-
apy to target the causative agents of many allergic diseases
and thereby prevent the activation of sentinel mechanisms
which initiate and sustain disease. In this review, we de-
scribed progress toward that ambitious objective for what is
arguably the most significant of all indoor allergens. The
power of the intervention exploits the growing awareness that
the allergome is not amolecular democracy: an exclusive cadre
of initiator allergens play decisive roles in driving disease.
This vulnerability creates a pharmacologic opportunity to
exert a broad spectrum of benefits by careful selection of target
and chemical design, as exemplified by the pioneer work with
ADIs. Naturally, it will be of considerable interest to follow the
progression into the clinic of the new drugs from this unique
program.
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TABLE 3
Potential strategic positioning of ADIs in allergic asthma versus alternative approaches
Intervention Examples Remarks
Allergen delivery inhibitors Group 1 HDM protease allergen inhibitors Small molecule
Inhaled delivery to target organ
Attractive profile (nonhuman target,
extracellular action) with disease modification
Root cause–directed
Potential to prevent exacerbations
Mechanistic differentiation
Potential addition to standard of care at
all levels of disease severity
Potentially prescribable at nonspecialist level
Low cost of goods compared with biologics
Exploitable as combination therapy and/or
other conditions
Alternative small molecules in
discovery/development
Downstream signal transduction and effector
mechanisms—various targets
Uncertain potential to surpass or add
significantly to inhaled steroids
Multiple redundant effector pathways are
confounders of efficacy
Potentially prescribable at
nonspecialist level
Low cost of goods compared with biologics
Biologics—approved or in development Anticytokine mAbs High cost of goods
Antireceptor mAbs Mainly applicable to severe disease only
Anti-IgE mAbs Inconvenient to use
Anti-IgE vaccine (pAb) Multiple redundant pathways are
confounders of efficacy
High safety barriers (esp. IgE vaccine)
Specialist use only
Patchy targeting of innate pathways
Immunotherapy Allergen-specific immunotherapy
Immune deviation
Moderately high cost of goods
Can be inconvenient to use
Specialists must be involved in GP use
Chronic safety of immune deviation
is unproven
Poor targeting of key innate pathways
GP, general practitioner; mAb, monoclonal antibody; pAb, polyclonal antibody.
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